Illumina Can't Revive DNA-Sequencing Patent Claims

Law360, Los Angeles (March 27, 2013, 8:08 PM EDT) -- A California federal judge on Wednesday refused to reconsider her prior art invalidation of nine method claims regarding a DNA-sequencing method patent owned by Illumina Inc., ruling that the company didn't offer any new rationale since her invalidation ruling favoring competitor Complete Genomics Inc.

In two Wednesday orders, U.S. District Judge Elizabeth LaPorte said Illumina didn't offer any substantially new rationale since her October ruling that the sequencing methods involved with Complete Genomics' genome-testing kits were dissimilar from the probes that Illumina's patent protected.

Also on...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.